Health concept

Dr. Wulf Dröge

 

Dr. Dröge was the first to describe the effect of glutathione on the immune response of a living organism (1986) and to discover the abnormally low cysteine and glutathione levels in HIV patients (1988-1989). In a series of clinical studies, Dr. Dröge investigated the effects of cysteine supplementation on the immune system in healthy humans and HIV patients and on weight loss in cachectic cancer patients. Dr. Dröge was also actively engaged in the design of clinical studies and organized research activities in cooperation with colleagues at McGill University and other leading scientific institutions. Dr. Dröge devoted more than forty years to basic and clinical research. His work ethic set the standard for the formulation of safe and effective new Immunotec products such as Immunocal Platinum.

 

After his doctorate at the University of Freiburg, Dr. Dröge conducted research at the Max-Planck Institute of Immunobiology in Freiburg, Germany, and the University of Minnesota, with renowned immunologist Dr. R.A. Good. Subsequently, he served for three years as a research fellow at Harvard University and for four years as a scientific member at the world-renowned Basel Institute for Immunology. What followed was an almost 30 year career as a professor of immunology and cell biology at the University of Heidelberg and head of the Department of Immunochemistry at the National Cancer Research Center of Germany (Deutsches Krebsforschungszentrum).

 

His international reputation in the field of redox physiology and aging research is based on more than 280 publications in international scientific journals. He focused his research in the areas of redox regulation and signaling pathways, pathogenesis of HIV infection, the mechanisms of disease-related wasting and aging, and the action of tumor necrosis factor.

 

He also published many articles in the fields of redox physiology, cancer and aging research and regularly gave student lectures at McGill University in Montreal.